MRK vs PFE
MRK and PFE side by side — valuation & fundamentals (public data).
Key statistics
| Metric | MRKMerck & Co., Inc. | PFEPfizer Inc. |
|---|---|---|
| Market cap | $321.60B | $142.66B |
| P/E (TTM) | 36.7 | 19.1 |
| P/B | 7.01 | 1.58 |
| P/S | 4.9x | 2.3x |
| Dividend yield | 2.54% | 6.85% |
| Revenue | $65.77B(TTM) | $63.31B(TTM) |
| Revenue growth (YoY) | 1.3% | -1.6% |
| Net income | $8.94B(TTM) | $7.49B(TTM) |
| Earnings growth (YoY) | 6.6% | -3.2% |
| EPS, diluted | $3.55(TTM) | $1.31(TTM) |
| EBIT margin | 34.2% | 16.3% |
| ROE | 39.8% | 8.6% |
| ROIC | 21.5% | 6.7% |
| 1y total return | +70.8% | +14.8% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: MRK frente a PFE
| Métrica | MRK | PFE |
|---|---|---|
| Valor final | $33.5K | $13.3K |
| Retorno total | +235.1% | +33.2% |
| CAGR | +12.4% | +2.8% |
| Volatilidad | 22.9% | 23.9% |
| Sharpe | 0.46 | 0.08 |
| Sortino | 0.67 | 0.11 |
| Caída máxima | -43.4% | -59.0% |
Basado en 2600 días de negociación comunes, 2016-03-30 → 2026-07-31 · tasa libre de riesgo 3.83% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)